Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,